Daniel J van Wamelen

Dr. Daniel J van Wamelen

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
KGKings Parcog groupMDS Nonmotor study group
Kings Parcog groupMDS Nonmotor study group
ELEe Wei Lim
Ee Wei Lim
DADag Aarsland
Dag Aarsland
DFDominic Ffytche
Dominic Ffytche
Raquel Natalia TaddeiRaquel Natalia Taddei
Raquel Natalia Taddei
KCKallol Ray Chaudhuri
Kallol Ray Chaudhuri

19 August 2020 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
PDF file
Daniel J van WamelenDaniel J van Wamelen
Daniel J van Wamelen
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
DWDaniel Weintraub
Daniel Weintraub
ASAnette Schrag
Anette Schrag
Angelo AntoniniAngelo Antonini
Angelo Antonini
IGInternational Parkinson and Movement Disorder Society Parkinson's Disease Non‐Motor Study Group
International Parkinson and Movement Disorder Society Parkinson's Disease Non‐Motor Study Group
The Non‐Motor Symptoms Scale (NMSS) was developed and validated in 2007 as the first instrument for the comprehensive assessment of a range of non‐motor symptoms in Parkinson's disease (PD). Thirteen years have elapsed since its introduction and extensive international validation with good psychometric attributes has been carried out. Here, we review the validation data of the NMSS and its cross‐validity with other scales, and describe the key evidence derived from use of the NMSS in clinical studies. To date, over 100 clinical studies and trials have made use of it as an outcome measure, showing consistent and strong correlations between NMSS burden and health‐related quality of life measures. Moreover, the scale has shown to be capable of detecting longitudinal changes in non‐motor symptoms, where studies have shown differential changes over time of several of the NMSS domains. The scale has become a key outcome in several randomised clinical trials. Highlighting the prevalence and importance of non‐motor symptoms to quality of life in patients with PD, the development of NMSS has also been useful in signposting clinical and biomarker based research addressing non‐motor symptoms in PD.

23 September 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GWGreta K. Wood
Greta K. Wood
BSBrendan F. Sargent
Brendan F. Sargent
ZAZain-Ul-Abideen Ahmad
Zain-Ul-Abideen Ahmad
KTKukatharmini Tharmaratnam
Kukatharmini Tharmaratnam
CDCordelia Dunai
Cordelia Dunai
ELE. Charles Leek
E. Charles Leek
The spectrum, pathophysiology and recovery trajectory of persistent post-COVID-19 cognitive deficits are unknown, limiting our ability to develop prevention and treatment strategies. We report the 1-year cognitive, serum biomarker and neuroimaging findings from a prospective, national study of cognition in 351 COVID-19 patients who required hospitalization, compared with 2,927 normative matched controls. Cognitive deficits were global, associated with elevated brain injury markers and reduced anterior cingulate cortex volume 1 year after COVID-19. Severity of the initial infective insult, postacute psychiatric symptoms and a history of encephalopathy were associated with the greatest deficits. There was strong concordance between subjective and objective cognitive deficits. Longitudinal follow-up in 106 patients demonstrated a trend toward recovery. Together, these findings support the hypothesis that brain injury in moderate to severe COVID-19 may be immune-mediated, and should guide the development of therapeutic strategies.

4 March 2020 in Dysphagia
Verified
Journal Article
Open access
PDF file
Daniel J van WamelenDaniel J van Wamelen
Daniel J van Wamelen
VLValentina Leta
Valentina Leta
JJJulia Johnson
Julia Johnson
COClaudia Lazcano Ocampo
Claudia Lazcano Ocampo
APAleksandra M. Podlewska
Aleksandra M. Podlewska
KCK. Ray Chaudhuri
K. Ray Chaudhuri
Sialorrhoea in Parkinson’s disease (PD) is an often neglected yet key non-motor symptom with impact on patient quality of life. However, previous studies have shown a broad range of prevalence figures. To assess prevalence of drooling in PD and its relationship to quality of life, we performed a retrospective analysis of 728 consecutive PD patients who had a baseline and follow-up assessment as part of the Non-motor International Longitudinal Study (NILS), and for whom drooling presence and severity were available, assessed through the Non-Motor Symptoms Scale (NMSS). In addition, we analysed the prevalence of associated dysphagia through self-reported outcomes. Quality of life was assessed through the PDQ-8 scale. Baseline (disease duration 5.6 years) prevalence of drooling was 37.2% (score ≥ 1 NMSS question 19), and after 3.27 ± 1.74 years follow-up, this was 40.1% (p = 0.17). The prevalence of drooling increased with age (p < 0.001). The severity of drooling, however, did not change (p = 0.12). While in 456 patients without drooling at baseline, only 16% (n = 73) had dysphagia (question 20 of the NMSS), in those with drooling this was 34.3% (p < 0.001). At follow-up, the number of patients with dysphagia had increased, 20.4% with no drooling had dysphagia, and 43.6% with drooling had dysphagia. Both at baseline and follow-up, drooling severity was significantly positively associated with quality of life (PDQ-8; r = 0.199; p < 0.001). In moderately advanced PD patients, subjective drooling occurs in over one-third of patients and was significantly associated with decreased quality of life. Dysphagia occurred significantly more often in patients with drooling.

2 August 2021 in Journal of Parkinson’s Disease
Verified
Journal Article
Closed access
PDF file
VLValentina Leta
Valentina Leta
DUDaniele Urso
Daniele Urso
LBLucia Batzu
Lucia Batzu
DWDaniel Weintraub
Daniel Weintraub
NTNataliya Titova
Nataliya Titova
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
Background: Constipation is regarded as one of the prodromal features of Parkinson’s disease (PD) and there is emerging evidence linking gastrointestinal dysfunction and cognitive impairment (CI) in PD. Objective: We explored whether constipation is associated with development of CI in two independent cohorts of de novo PD patients (n = 196 from the Non-motor International Longitudinal Study [NILS] and n = 423 from the Parkinson’s Progression Markers Initiative [PPMI] study). Methods: Constipation was clinically defined using the Non-Motor Symptoms Scale (NMSS) item-21 [NILS] and Scales for Outcomes in PD-Autonomic (SCOPA-AUT) item-5 [PPMI]. We assessed baseline group differences (PD with or without constipation) in CI, global non-motor symptoms burden, motor dysfunction, and striatal dopaminergic denervation. Kaplan-Meier method estimated group differences in cumulative proportion of patients with incident CI over three years. In PPMI, we subsequently performed univariate and multivariate Cox survival analyses to evaluate whether constipation predicts incident mild cognitive impairment or dementia over a 6-year period, including constipation and other known predictors of CI as covariates. Results: Patients with constipation had greater motor and global non-motor burden in both cohorts at baseline (p < 0.05). Kaplan-Meier plots showed faster conversion to CI in patients with constipation in both cohorts (p < 0.05). In PPMI, 37 subjects developed dementia during a mean follow-up of 4.9 years, and constipation was an independent predictor of dementia onset (hazard ratio = 2.311; p = 0.02). Conclusion: Constipation in de novo PD patients is associated with development of cognitive decline and may serve as a clinical biomarker for identification of patients at risk for cognitive impairment.

1 August 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
Daniel J van WamelenDaniel J van Wamelen
Daniel J van Wamelen
JSJirada Sringean
Jirada Sringean
DTDhaval Trivedi
Dhaval Trivedi
CCCamille B. Carroll
Camille B. Carroll
ASAnette E. Schrag
Anette E. Schrag
KCK. Ray Chaudhuri
K. Ray Chaudhuri